Malaga (EFE) .- The improvement of asthma treatment has been addressed by experts from the Biomedical Research Institute of Malaga (Ibima). These have participated in a reference article published in ‘Allergy’. In the publication, new strategies are also treated to improve the quality of life of patients.
The inhaled prolonged muscarinic antagonists (LAMA) were initially developed to treat chronic obstructive pulmonary disease (COPD). This was reported this Friday the Ibima in a statement.
However, its effectiveness has also been demonstrated in asthmatic patients. This is because it reduces serious exacerbations and improve lung function.
“We are facing an important advance that will improve the therapeutic approach in people with asthma that fail to properly control their disease with the usual treatments.” It was highlighted by Dr. Ibon Eguíluz, main author of the article.
Great clinical projection
He added that “the use of lama in asthma remains an emerging field, but with great clinical projection.”
One of the main current challenges is to accurately define the patient profile that can benefit more from this therapeutic option. Also, establish its place within the integral management of asthma.
The work led by Ibima has focused on identifying those key characteristics. At the same time, in proposing a prescription protocol that optimizes its use.
Eguíluz has explained that, “after years of collaboration, a set of clinical criteria that allow the indication of Lama in asthma with more security and efficiency has been agreed.” Similarly, he hopes that “this will contribute to improving the quality of life of many patients who do not respond well to conventional therapies.”
The study has also revealed anti -inflammatory properties of the LAMA. These were so far little valued in the context of asthma.
New perspective
It has been proven that these drugs reduce the presence of leukocytes in the bronchial tissue. This implies a new perspective on its mechanism of action and suggests additional benefits in patients with a marked inflammatory component.
“International collaboration has been fundamental to provide the study of the necessary rigor and depth.” > This is what Dr. Almudena Testera, of the Regional Hospital of Malaga has pointed out.
“We believe that our findings can guide clinical practice and open new lines of research on the use of these drugs in asthma.” He has added Testera.
This study marks a significant step towards a more adjusted approach to the individual characteristics of each asthmatic patient. Also the ability to better select the appropriate candidates for LAMA therapy could reduce the number of therapeutic failures and optimize health system resources.
